Genoptix/Novartis
On January 24, 2011, Genoptix, Inc. (Nasdaq: GXDX) announced hat it has entered into a definitive merger agreement to be acquired by Novartis (NYSE: NVS).
Under the agreement, Novartis will commence an all cash tender offer for all outstanding shares of common stock of Genoptix at $25 per share, or total consideration of $470 million in equity and $330 million of enterprise value.
Closing is expected in H111.
Barclays Capital is serving as financial advisor to Genoptix and Cooley LLP is serving as Genoptix' legal advisor.
Under the agreement, Novartis will commence an all cash tender offer for all outstanding shares of common stock of Genoptix at $25 per share, or total consideration of $470 million in equity and $330 million of enterprise value.
Closing is expected in H111.
Barclays Capital is serving as financial advisor to Genoptix and Cooley LLP is serving as Genoptix' legal advisor.
View Older Stories
-
OrthoPediatrics (KIDS) Appoints Samuel Riccitelli to its Board of Directors
-
Tandem Diabetes (TNDM) Reports Leigh Vosseller to Succeed John Cajigas as CFO
-
NanoString Technologies (NSTG) Highlights Validation of to Expand Business Communications Offerings in Sweden at AACR Meeting, 4/1-4/5
-
MEI Pharma (MEIP) Appoints New Board Chair
-
S&P Announces Changes to US Indices: (NCI) for (GXDX) in SmallCap 600, (NOG) for NCI in MidCap 400
-
Unusual 11 Mid-Day Movers 01/24: CLDA, OCCF, NVGN, SSCC, RNN, GXDX Higher; APP, WHX, RSH, ONSM, GENE Lower
-
This Hedge Fund Guru Profited Big-Time From the Buyout of Genoptix (GXDX), See What Other Targets He Is Buying
-
Notable Mergers and Acquisitions of the Day 01/24: RKT/SSCC, NVS/GXDX, GE, HTGC
-
Morning Movers 01/24: CLDA, NVGN, SSCC, GXDX, OCCF, RNN, CWST, SILC, PSTI Higher; RSH, GENE, SRX, OVTI Lower
